Efficacy of Nutritional Support and Prehabilitation in Patients who have Resectable Pancreatic Ductal Adenocarcinoma and Undergo Preoperative Chemotherapy: Non-Blinded Randomized Controlled Trial

Hasegawa Kiyoshi0 个研究点目标入组 60 人开始时间: 2023年2月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. With resectable pancreatic cancer scheduled for neoadjuvant chemotherapy, gemcitabine and S-1, and pancreatic resection
•2. ASA performance status of 1-2
•3. Aged between 18 and 85 years old at the time of informed consent is taken
•4. Male or female
•5. Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
•6. Able to attend all scheduled visits

•1. Having history of hypersensitivity to component of ENORAS Liquid
•2. With milk protein allergy
•3. With ileus
•4. With loss of bowel function
•5. With severe liver diseases, renal diseases or cardiac diseases, judged based on grade 3 of CTCAE v5.0- JCOG
•6. Having hemodialysis
•7. With disorder of glucose metabolism such as severe diabetes mellitus
•8. With congenital disorder of amino acid metabolism
•9. Women of childbearing potential, pregnant women or breast-feeding women
•10. Disable to having prehabilitation due to impaired cardiopulmonary function
•11. Judged as ineligible by clinical investigators

发起方

Hasegawa Kiyoshi